CCR News and Events

HIV infecting healthy cell

Unlocking the key to HIV persistence

Even though antiretroviral therapies have allowed many people to live long lives, ridding the body of HIV completely has been an elusive goal ever since the discovery in the 1980s that HIV causes AIDS. New research from the Center for Cancer Research shows that proviral DNA sequences and their integration at specific sites could provide clues for researchers developing drugs to eradicate AIDS. Read more...

Hernandez clinical trial conversation

Clinical Trial Conversation: Jonathan Hernandez describes metastatic colorectal cancer clinical trial

Jul 8, 2019

Colorectal cancer (CRC) starts in the colon and/or rectum and often metastasizes, or spreads, to many sites in the body. In a certain set of patients, however, CRC metastasizes only to the liver. Jonathan Hernandez, M.D., of the Surgical Oncology Program, is leading a new clinical trial to study how well CRC patients with liver-only metastases respond to treatment with a hepatic artery infusion pump. Dr. Hernandez describes the trial in this new video. Read more...

Jonathan Hernandez

Jonathan Hernandez discusses surgical oncology with Behind the Knife podcast

Jul 2, 2019

Jonathan Hernandez, M.D., Investigator in the Surgical Oncology Program, was recently featured in a Behind the Knife podcast. During the episode, Dr. Hernandez discussed the surgical oncology match process and his research on ex vivo tissue preservation to study tumors. The full podcast is available online. Read more...

rhabdosarcoma cells

Sarcoma Awareness Month

Jul 1, 2019

July is Sarcoma Awareness Month and we are highlighting our researchers who are advancing research discovery in this field. Read more...

Combination IL-15

Clinical trial tests immunotherapy combination to treat T-cell cancers

Jun 28, 2019

The Center for Cancer Research’s Lymphoid Malignancies Branch is testing a combination treatment for patients whose mature T-cell cancer has returned after therapy or has not responded to therapy using avelumab, an immunotherapy agent that enhances the activity of immune cells and blocks a protein pathway that allows cancer cells to hide from the immune system. Read more...

HPV 16

Clinical trial will test immunotherapy against precancerous vulvar lesions

Jun 27, 2019

Scientists at the Center for Cancer Research are launching a phase II clinical trial to evaluate the effect of a single immunotherapy treatment on precancerous lesions that put women at risk for vulvar cancer. Like the cell-based immunotherapies now used to treat certain blood cancers, the experimental treatment aims to use patients’ own immune cells to fight disease. Read more...

T cells

Gastrointestinal tumors harbor T cells that recognize patients’ unique tumor antigens

Jun 25, 2019

CCR scientists, led by Steven A. Rosenberg, M.D., Ph.D., have determined that many common gastrointestinal tumors bear mutations capable of eliciting an immune response, suggesting that immunotherapy could be an effective way to treat these common cancers.  Read more...

Human T cell (blue) is under attack by HIV (yellow)

Research shows long noncoding RNA influences expression of key HIV receptor

Jun 24, 2019

New research from the Center for Cancer Research has identified a long noncoding RNA that influences the expression of CCR5, a receptor that HIV uses to infect immune cells. The finding points to the molecule as a potential marker that indicates a patient’s susceptibility to the virus. Read more...


Pediatric Oncology Branch patient shares neurofibromatosis journey at NIH

Jun 18, 2019

Xavier, a patient in the Pediatric Oncology Branch, was born with an incompletely formed leg bone and a large number of dark spots all over his body. When Xavier broke his weak leg at only 11 months of age, he was diagnosed with neurofibromatosis type 1 (NF1). He came to the NIH for treatment, and his tumors have shrunk by more than 20 percent thanks to treatment with selumetinib. Read more...

Live-cell fluorescence imaging showing Rabin8, labeled green, binding to Rab11a, labeled red, minutes after serum starvation in

Akt protein kinase pathway regulates key step in the initiation of cilia formation

Jun 13, 2019

CCR investigators have discovered that activating the Akt protein kinase pathway stabilizes the binding of the WDR44 protein to the Rab11 protein. This prevents Rab11 from binding to the Rabin8 protein, thereby blocking cilia formation. When Akt is inactive, though, Rab11 instead is bound by FIP3, enhancing its binding to Rabin8, which helps initiate cilia formation. Since abnormalities in cilia formation are associated with a number of types of cancer, these findings point to several potential targets for cancer therapy.   Read more...

oral squamous cancer cell (white) being attacked by two cytotoxic T cells (red), part of a natural immune response

Registration now open for Cancer and Inflammation: From Micro to Macro

Jun 12, 2019

The Cancer and Inflammation: From Micro to Macro conference, hosted by the CCR Center of Excellence in Immunology, will take place October 17-18, 2019. This two-day national symposium addresses recent advances in the field and should be an exciting forum for discussion and debate on the current understanding of cancer and inflammation. Read more...